Financing channel feed

Sir­naomics puts off an IPO a lit­tle longer as it pock­ets an­oth­er megaround. Is an S-1 around the cor­ner this time?

4 years ago
China

Vet­er­an amy­loid cham­pi­on helps Alzheimer's start­up grab $160M in IPO as in­vestors charge back in to a once fad­ed field

4 years ago
R&D

From base­ment lab to Wall Street: Ab­sci looks to bring its 'pro­tein print­ing' plat­form pub­lic

4 years ago

Ac­tivist El­liott be­gins its long-await­ed at­tack on CEO Em­ma Walm­s­ley and a Glax­o­SmithK­line that has 'lost its way'

4 years ago
Deals

Say good­bye to plants: Syn­bio play­er An­theia earns new back­ers in quest to re­design flo­ra-de­rived med­i­cine man­u­fac­tur­ing

4 years ago

A dry-pow­der lung dis­ease drug and next-gen an­tibi­otics: Two biotechs and an $880M slate of SPACs land on Wall Street with big ideas

4 years ago

Bask­ing in lime­light of a CRISPR break­through, In­tel­lia bags $600M cash raise as shares soar to all-time high

4 years ago

Gilead, Fore­site take an un­known pan­dem­ic an­tivi­ral pub­lic in $250M SPAC deal

4 years ago
Deals

Gold­man Sachs backs clin­i­cal tri­al ser­vices in the cloud with $230M eq­ui­ty play amid de­cen­tral­ized study craze

4 years ago

Promis­es of a next-gen se­quenc­ing ap­proach earn El­e­ment Bio­sciences a hefty Se­ries C. Is an IPO next?

4 years ago

Eras­ing can­cer, re­viv­ing on­colyt­ic virus, treat­ing a rare neu­ro­mus­cu­lar con­di­tion: Here's what you need to know about the 5 new biotechs fil­ing for IPOs

4 years ago

Graphite Bio leads this week's IPO squad, look­ing to turn the tide on sick­le cell dis­ease with gene edit­ing

4 years ago

Langer lab spin­out Lyn­dra rais­es $60.5M in bid to re­place ex­ist­ing HIV, schiz­o­phre­nia, opi­oid abuse treat­ments

4 years ago

Monte Rosa takes this week's IPO lead as a nine-fig­ure raise push­es in­dus­try to­tal past $9B

4 years ago

Arie Bellde­grun's Vi­da Ven­tures goes back to the well with $825M mega­fund and its eyes set on more in­no­v­a­tive meds

4 years ago

Chas­ing 'Holy Grail' STAT3 tar­get, Hous­ton start­up re­fu­els with $74M to ze­ro in on liv­er can­cer

4 years ago

A pair of for­mer MIT re­searchers think they've un­locked the next gen­er­a­tion of mR­NA us­ing syn­bio 'log­ic cir­cuit­s'

4 years ago
Startups

In­vestors give Orum Ther­a­peu­tic­s' unique take on pro­tein de­graders an­oth­er nudge to­ward the clin­ic

4 years ago

Third Rock seeds cell ther­a­py start­up with $95M in bid to cure MS

4 years ago
Startups
Cell/Gene Tx

San Fran­cis­co-area biotech gets new cash to launch clin­i­cal pro­gram for con­gen­i­tal sug­ar pro­cess­ing dis­ease

4 years ago

Stephen Elledge's Har­vard lab again proves fruit­ful with the launch of high-through­put an­ti­body start­up

4 years ago

Neu­rona Ther­a­peu­tics is dash­ing to the clin­ic with its cell ther­a­py for epilep­sy — but first, an­oth­er ven­ture round

4 years ago
R&D

A Re­cur­sion vet­er­an is map­ping plant life to chart a course to new ther­a­pies — and in­vestors like what they see

4 years ago
AI

Big Phar­ma back­ers jump on board 'Treg' car­tog­ra­pher's lead round with up to six can­di­dates in the pipe

4 years ago
First page Previous page 71727374757677 Next page Last page
A service from the Financial Times